Martine Rothblatt is a visionary entrepreneur and biotechnologist, currently serving as the Chairperson and Chief Executive Officer of United Therapeutics Corporation. Born on July 10, 1954, Rothblatt's career trajectory has been marked by groundbreaking achievements in various fields. She holds a J.D. from UCLA School of Law and a Ph.D. in Medical Ethics from the Royal London Medical College. Before founding United Therapeutics in 1996, Rothblatt was instrumental in launching Sirius Satellite Radio, where she served as the CEO until 1992. Her pioneering work in satellite communications and biotechnology underscores her diverse expertise and innovative approach to business. At United Therapeutics, Rothblatt has steered the company to the forefront of the biotechnology industry, focusing on developing novel pharmaceutical therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). Under her leadership, United Therapeutics has successfully brought several life-saving drugs to market, significantly improving the quality of life for patients worldwide. Rothblatt's commitment to innovation is evident in the company's ongoing research into organ manufacturing and 3D bioprinting, aiming to address the critical shortage of transplantable organs. Her strategic vision and dedication to advancing medical science have solidified United Therapeutics' position as a leader in the field. Beyond her corporate achievements, Martine Rothblatt is a prolific author and thought leader, advocating for transhumanism and the ethical implications of advanced technology. Her books, including "The Apartheid of Sex" and "Virtually Human," explore themes of gender identity, artificial intelligence, and the future of humanity. Rothblatt's multifaceted career and relentless pursuit of scientific advancement continue to inspire and influence the biotechnology industry and beyond.